Physician profile
Michael S Cunningham
NPI 1548253461
$3,402.45
in general payments reported to CMS, 2019-2025
24 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $206 · 2021: $597 · 2022: $374 · 2023: $191 · 2024: $294 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $581.61 | 2019-2024 | Ensite Precision |
| Amgen INC. | $478.87 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $293.84 | 2019-2020 | |
| Abiomed | $246.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $222.07 | 2019 | |
| Edwards Lifesciences Corporation | $199.95 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals Lp | $161.98 | 2019-2024 | Farxiga |
| Akcea Therapeutics, INC. | $156.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $149.27 | 2019-2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $139.28 | 2019-2021 | |
| Intuitive Surgical, INC. | $108.52 | 2025 | |
| Pfizer INC. | $100.52 | 2019-2021 | |
| Novo Nordisk INC | $92.19 | 2025 | |
| Braemar Manufacturing, LLC | $77.58 | 2019 | |
| Astellas Pharma US INC | $75.62 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.75 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $57.18 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.95 | 2019 | |
| Gilead Sciences, INC. | $48.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.37 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.29 | 2019 | |
| Biotronik INC. | $17.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.92 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.